Levetiracetam – a drug that can be used not only in the treatment of epilepsy
Levetiracetam, which belongs to the new generation of antiepileptic drugs, has a unique and not well-known mechanism of action. The drug affects the release of neurotransmitters through the binding to the synaptic vesicle protein SV2A. Moreover, it acts on calcium channels, inhibits glutamatergic ne...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Index Copernicus International S.A.
2019-09-01
|
| Series: | Postępy Higieny i Medycyny Doświadczalnej |
| Subjects: | |
| Online Access: | http://phmd.pl/gicid/01.3001.0013.4670 |
| Summary: | Levetiracetam, which belongs to the new generation of antiepileptic drugs, has a unique and not well-known mechanism of action. The drug affects the release of neurotransmitters through the binding to the synaptic vesicle protein SV2A. Moreover, it acts on calcium channels, inhibits glutamatergic neurotransmission and affects GABA-ergic neurotransmission through e.g. the Zn²⁺-induced suppression of GABAA-mediated presynaptic inhibition and the modulation of the action of GABAA antagonists. Levetiracetam has also neuroprotective activity which is associated with the influence on transcription processes, neurotransmission, antioxidant and anti-inflammatory activity. The results of recent research indicate that this complex action creates the prospect of using it in the alleviation of epileptogenesis, poststroke seizuires, seizure prophylaxis in brain injured patients and diabetic neuropathy. Furthermore, the drug may also have a beneficial effect in the treatment of Alzheimer patients with epileptic seizures and levodopa-induced dyskinesias in Parkinson’s disease.
|
|---|---|
| ISSN: | 0032-5449 1732-2693 |